Announcement
19 Dec 2025
In December 2025, the United States government announced an agreement with GSK to implement most-favoured-nation drug pricing for American patients.
Source
Sign in to access
Number of interventions
4
0 certainly harmful
4 likely harmful
0 liberalising
List of interventions
Implementation date
No implementation date
Revocation date:
No revocation date
Updated: 05 Apr 2026
Local operations incentive
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced an agreement with GSK. Under the agreement, GSK will be exempt from Section 232 tariffs for three years, in exchange for the company's commitm...
Sign in to see more
Updated: 05 Apr 2026
FDI: Financial incentive
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced an agreement with GSK. Under the agreement, GSK committed to make investments in R&D and manufacturing in the United States. In return, GS...
Sign in to see more
Updated: 05 Apr 2026
Tax or social insurance relief
Recent update from 05 Apr 2026:
On 19 December 2025, the U.S. Administration announced reaching an agreement with GSK. Under the agreement, GSK will be exempt from Section 232 tariffs for three years, provided that the company ma...
Sign in to see more
Updated: 05 Apr 2026
Import tariff
Recent update from 05 Apr 2026:
On 19 December 2025, the United States announced an agreement with GSK providing the company with a three-year exemption from Section 232 tariffs on pharmaceutical products. In exchange, GSK agreed...
Sign in to see more
Threads
See all
This state act is not part of any Thread yet.